1. LMWHs dosage and outcomes in acute pulmonary embolism with renal insufficiency, an analysis from a large real-world study.
- Author
-
Wang, Dingyi, Fan, Guohui, Lei, Jieping, Yang, Yuanhua, Xu, Xiaomao, Ji, Yingqun, Yi, Qun, Chen, Hong, Hu, Xiaoyun, Liu, Zhihong, Mao, Yimin, Zhang, Jie, Shi, Juhong, Zhang, Zhu, Wu, Sinan, Tao, Xincao, Xie, Wanmu, Wan, Jun, Zhang, Yunxia, and Zhang, Shuai
- Subjects
HEMORRHAGE risk factors ,ENOXAPARIN ,CAUSES of death ,LENGTH of stay in hospitals ,PULMONARY embolism ,CONFIDENCE intervals ,KIDNEY failure ,ANTICOAGULANTS ,TREATMENT effectiveness ,LOW-molecular-weight heparin ,DESCRIPTIVE statistics ,HOSPITAL care ,ODDS ratio ,ACUTE diseases ,CREATININE - Abstract
Background: Renal function is associated with prognoses for acute pulmonary embolism (PE). Objective: To investigate the application of anticoagulants and dosage of LMWH among patients with renal insufficiency (RI), and the association between LWMH dosage and the patients' in-hospital outcomes. Methods: Adult patients diagnosed with non-high risk acute PE from 2009 to 2015, with available data of creatinine clearance (CCr) were enrolled from a multicenter registry in China. Renal insufficiency (RI) was defined as CCr < 60 ml/min. LMWH dosage was converted into IU/kg daily dose and presented as adjusted dose (≤ 100 IU/kg/day) and conventional dose (> 100 IU/kg/day). All-cause death, PE-related death and bleeding events during hospitalization were analyzed as endpoints. Results: Among the enrolled 5870 patients, RI occurred in 1311 (22.3%). 30 ≤ CCr < 60 ml/min was associated with higher rate of bleeding events and CCr < 30 ml/min was associated with all-cause death, PE-related death and major bleeding. Adjusted-dose LMWH was applied in 26.1% of patients with 30 ≤ CCr < 60 ml/min and in 26.2% of CCr < 30 ml/min patients. Among patients with RI, in-hospital bleeding occurred more frequently in those who were administered conventional dose of LMWH, compared with adjusted dose (9.2% vs 5.0%, p = 0.047). Adjusted dose of LMWH presented as protective factor for in-hospital bleeding (OR 0.62, 95%CI 0.27–1.00, p = 0.0496) and the risk of bleeding increased as length of hospital stay prolonged (OR 1.03, 95%CI 1.01–1.06, p = 0.0014). Conclusions: The proportion of adjusted usage of LMWH was low. The application of adjusted-dose LMWH was associated with lower risk of in-hospital bleeding for RI patients, in real-world setting of PE treatment. Anticoagulation strategy for RI patients should be paid more attention and requires evidence of high quality. Trial Registration: The CURES was registered in ClinicalTrias.gov, identifier number: NCT02943343. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF